Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee

Zimmer Biomet logo

Zimmer Biomet




Avascular Necrosis of the Femoral Condyle
Traumatic Arthritis
Flexion Deformities
Moderate Varus


Device: NexGen LPS-Flex Mobile Bearing Knee

Study type


Funder types




Details and patient eligibility


The purpose of the study is to assess the long-term performance of the NexGen LPS-Flex Mobile Bearing Knee in the treatment of patients with severe knee pain or degenerative knee disease.

Full description

The NexGen LPS-FLex Mobile Bearing Knee received FDA approval for commercial distribution in the US on December 10, 2007. The approval was in accordance with a "condition of approval" to perform a 10-year post approval study to evaluate the longer-term safety and effectiveness of the LPS-Flex Mobile Bearing Knee. The post approval study will consist of patients from the investigational device exemption study arm (Group 1) as well as patients who are eligible for a total knee replacement and have been chosen to receive the LPS-Flex Mobile Knee (Group 2). Group 1 will be followed from 4 years through a total of 10 years from the date of surgery. Group 2 will be followed from pre-op through a total of 5 years from the date of surgery.


266 patients




Accepts Healthy Volunteers

Inclusion criteria

  • Osteoarthritis
  • Primary and secondary traumatic arthritis
  • Avascular necrosis of the femoral condyle
  • Moderate varus, valgus, or flexion deformities (i.e. valgus/varus deformity of less than or equal to 15 degrees, fixed flexion deformity of less than or equal to 10 degrees)

Exclusion criteria

  • Previous history of infection in the affected joint and/or local/systemic infection that may affect the prosthetic joint
  • Insufficient bone stock on femoral or tibial surfaces
  • Skeletal immaturity
  • Neuropathic arthropathy
  • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb
  • A stable, painless arthrodesis in a satisfactory functional position
  • Severe instability secondary to the absence of collateral integrity
  • Total knee arthroplasty is contraindicated in patients who have rheumatoid arthritis (RA) and an ulcer of the skin or a history of recurrent breakdown of the skin because their risk of postoperative infection is greater. RA patient using steroids may also have increased risk of infection. Late infections in RA patients have been reported 24+ months postoperative.
  • Patient is a poor compliance risk, i.e., history of ethanol or drug abuse, or mental handicap that would compromise patient compliance with respect to rehabilitation or follow-up
  • Patient is not willing or able to give informed consent to participate in the follow-up program
  • Patient is not willing to return for all scheduled follow-up appointments as defined by this protocol.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

266 participants in 2 patient groups

Post-Approval Study Group (Group 2)
Experimental group
Subjects enrolled in a short-term study (5 years) consisted of cases eligible to receive the LPS-Flex Mobile Bearing Knee implanted by orthopedic surgeons experienced in primary total knee replacement. All Group 2 subjects, both unilateral and bilateral subjects, are in the same arm of the study. As part of the PAS study, these subjects were followed from Pre-operative to 5 years.
Device: NexGen LPS-Flex Mobile Bearing Knee
Investigational Device Exemption Group (Group 1)
Experimental group
Subjects who were implanted with either the LPS Flex Fixed Bearing Knee (control population) or the LPS Flex Mobile Bearing Knee device during the previous Investigational Device Exemption study. As part of the PAS study, these subjects were followed from 4 years to 10 years.
Device: NexGen LPS-Flex Mobile Bearing Knee

Trial documents

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems